Back to results
US 2014/0227277 A1Published application
Combination therapy with an anti-CD19 antibody and a purine analog
AssigneeMorphosys AG
InventorsJutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
Life of this patent
Estimating the term…
Abstract
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Claims9
A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-competes with an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO:
- 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO:
- 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO:
- 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO:
- 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO:
- 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO:
- 6) and fludarabine for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
3 more elements
Dependencies are inferred from the claim text.